1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, Rodríguez-Antona C.

    Regulatory Polymorphisms in beta-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

    CLINICAL CANCER RESEARCH . 18(16): 4441-4448. Nº de citas: 53

    [doi:10.1158/1078-0432.CCR-12-1221]

  • Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón y Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J.

    Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

    MOLECULAR AND CELLULAR ENDOCRINOLOGY . 358(2, SI): 244-255. Nº de citas: 40

    [doi:10.1016/j.mce.2011.10.003]

  • Sánchez-Rovira P, Antón A, Barnadas A, Velasco A, Lomas M, Rodríguez-Pinilla M, Ramírez JL, Ramírez C, Ríos MJ, Castellá E, García-Andrade C, San Antonio B, Carrasco E, Palacios JL.

    Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study

    CLINICAL & TRANSLATIONAL ONCOLOGY . 14(6): 430-436. Nº de citas: 10

    [doi:10.1007/s12094-012-0820-4]

  • Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

    Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

    JOURNAL OF PATHOLOGY . 227(1): 42-52. Nº de citas: 111

    [doi:10.1002/path.3990]

  • Durán-Prado M, Gahete MD, Hergueta-Redondo M, Martínez-Fuentes AJ, Córdoba-Chacón J, Palacios J, Gracia-Navarro F, Moreno-Bueno G, Malagón MM, Luque RM, Castaño JP.

    The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells

    Oncogene . 31(16): 2049-2061. Nº de citas: 54

    [doi:10.1038/onc.2011.389]

  • Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

    Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer

    Annals of oncology : official journal of the European Society for Medical Oncology . 23(3): 625-631. Nº de citas: 93

    [doi:10.1093/annonc/mdr278]

  • Santacana M, Yeramian A, Velasco A, Bergada L, Gatius S, García V, Azueta A, Palacios J, Dolcet X, Oliva E, Matias-Guiu X.

    Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia

    Histopathology . 60(3): 460-471. Nº de citas: 12

    [doi:10.1111/j.1365-2559.2011.04106.x]

  • Moch H, Blank PR, Dietel M, Elmberger G, Kerr KM, Palacios J, Penault-Llorca F, Rossi G, Szucs TD.

    Personalized cancer medicine and the future of pathology

    VIRCHOWS ARCHIV . 460(1): 3-8. Nº de citas: 27

    [doi:10.1007/s00428-011-1179-6]

  • Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

    Functional characterization of the 19q12 amplicon in grade III breast cancers

    BREAST CANCER RESEARCH . 14(2): . Nº de citas: 51

    [doi:10.1186/bcr3154]

  • Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

    Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers

    JOURNAL OF PATHOLOGY . 226(1): 84-96. Nº de citas: 105

    [doi:10.1002/path.2974]

  • Santón A, Cristóbal E, Aparicio M, Royuela A, Villar LM, Alvarez-Cermeño JC.

    High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis

    MULTIPLE SCLEROSIS JOURNAL . 17(11): 1295-1300. Nº de citas: 22

    [doi:10.1177/1352458511411063]

  • Gómez-Martín C, Concha A, Corominas JM, García-Caballero T, García-García E, Iglesias M, López JA, Ramón y Cajal S, Rojo F, Palacios J, Vera-Sempere F, Aranda E, Colomer R, García-Alfonso P, Garrido P, Rivera F, López-Ríos F.

    Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

    CLINICAL & TRANSLATIONAL ONCOLOGY . 13(9): 636-651. Nº de citas: 15

    [doi:10.1007/s12094-011-0709-7]

  • Doníz-Padilla L, Paniagua AE, Sandoval-Correa P, Monsiváis-Urenda A, Leskela S, Marazuela M, González-Amaro R.

    Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease

    EUROPEAN JOURNAL OF ENDOCRINOLOGY . 165(1): 129-136. Nº de citas: 9

    [doi:10.1530/EJE-11-0109]

  • Santón A, García-Cosío M, Cristóbal E, Pascual A, Muriel A, García-Laraña J.

    Expression of heat shock proteins in classical Hodgkin lymphoma: correlation with apoptotic pathways and prognostic significance

    Histopathology . 58(7): 1072-1080. Nº de citas: 10

    [doi:10.1111/j.1365-2559.2011.03803.x]

  • Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, Landa I, López-Jiménez E, Cascón A, Milne RL, Robledo M, Rodríguez-Antona C.

    Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

    PHARMACOGENOMICS JOURNAL . 11(2): 121-129. Nº de citas: 89

    [doi:10.1038/tpj.2010.13]

  • Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

    The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

    ENDOCRINE-RELATED CANCER . 18(1): 85-95. Nº de citas: 165

    [doi:10.1677/ERC-10-0148]

  • López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Diez-Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascón A.

    Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas

    MOLECULAR ENDOCRINOLOGY . 24(12): 2382-2391. Nº de citas: 153

    [doi:10.1210/me.2010-0256]

  • Figueroa-Vega N, Díaz A, Adrados M, Alvarez-Escolá C, Paniagua A, Aragonés J, Martín-Pérez E, Leskela S, Moreno-Otero R, González-Amaro R, Marazuela M.

    The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors

    ENDOCRINE-RELATED CANCER . 17(4): 897-908. Nº de citas: 18

    [doi:10.1677/ERC-10-0020]